Sponsor: Roche Pharmaceuticals
Sponsor Study ID: GO43878 (GLOBRYTE)
Study Title: Phase III, Open-label, Multicenter, Randomized Control Trial in Patients with r/r Mantle Cell Lymphoma to Evaluate the Efficacy, Safety and Pharmacokinetics of Glofitamab, a CD20xCD3 Bispecific Antibody
CTO #: 103816
NCT Number: NCT06084936
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Hematopoietic
Study Objectives: To evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of BR or R-Len with respect to PFS. To evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of BR or R-Len with respect to CRR. To evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of BR or R-Len with respect to ORR